#ChoiceBroking #Financial Tips Morning Tea:#NCC #BUY 76 Tgt 80 SL 75 #GLENMARK #BUY 935-940 TGT965 SL#925

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
NCC's July-September quarter earnings surpassed analysts' expectations on Tuesday. Standalone profit shot up 149 percent year-on-year to Rs 55 crore, driven by
lowertotalexpensesandinterestcostdespitefallinrevenue.Revenuedeclined6.7percenttoRs2,096.4croreduringthequartercomparedtoRs2,246croreinyear-
ago period. Numbers were ahead of estimates. Profit was estimated at Rs 36crore on revenue of Rs 1,821 crore and operating profit was expected at Rs 158 crore
with margin expansion of60basis points for thequarter.Operating profitincreased1.9percentyear-on-yeartoRs 184.4croreand margin expanded 70 basis points
to8.8percentinquarterendedSeptember2015,aidedbylowerrawmaterialcost.Rawmaterialcostduringthequarterplunged19.5percenttoRs1,080.9croreand
totalexpensesdeclined7.3percenttoRs1,940crorecomparedtoyear-agoperiod.Interestcostwasdown17percenttoRs131croreduringthequarteryear-on-year
asdebtdeclined9.3percenttoRs238croreattheendofSeptemberquarter(fromRs262.5croreinMarchquarter).OtherincomeonyearlybasisincreasedtoRs208
crorefromRs191.9crore.
Technical Outlook : On daily chart, the stock has been taking support of 50% Fibonacci retracement at 70.05 levels of its previous bull move 52.94
to 85.90. The stock has given breakout of falling trend line at 76.50 levels on hourly chart. Moreover, stock has been trading above 100 DEMA
on daily chart which indicates that long term trend is up. A momentum indicator RSI has remained above 40 level which point out for positive
breath in the stock. So for trading perspective, one could Buy in the range of 76.50-76 for the Target of 80 with the SL of 75.
NCC
GLENMARK
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
13th Nov 2015
Buy in the range of 940-935 for the Target of 965-975 with the SL of 925
Buy in the range of 76.50-76 for the Target 80 of with the SL of 75
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for
Clotrimazole and Betamethasone Dipropionate Cream USP, 1% 0.05%, the therapeutic equivalent of Lotrisone Cream USP, 1% 0.05% of Merck,
Sharp and Dohme Corporation. According to IMS Health sales data for the 12 month period ending September 2015, the Lotrisone Cream USP,
1% 0.05% market1 achieved annual sales of approximately $82.4 million. Glenmark's current portfolio consists of 103 products authorized for
distribution in the US marketplace and 63 ANDA's pending approval with the USFDA. In addition to these internal filings, Glenmark continues to
identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Technical Outlook: On daily chart, stock has been taking support of rising trend line at 935 levels. Moreover, prices have been trading above
200 DEMA which indicates long term trend is up. The Stock has been taking support of 61.8% Fibonacci retracement levels of its prevoius bull
move 698 to 1270. A momentum indicator RSI reading is in over sold zone at 37.50 level, which point out for bounce back in prices. So for
trading perspective, one could Buy in the range of 940-935 for the Target 965-975 of with the SL of 925.
AsianstockstrackedWallStreetlowerearlyFriday,withrisk-offsentimentinfullswingamidsharpfallsinthepriceofcommodities.Crudepriceshittwo-and-a-half-
monthlowsonThursdayaftertheUSgovernmentreportedastockpilebuildfourtimesabovemarketexpectations.WestTexasIntermediatecrudewaslastseen0.3
percentlowerat$41.62abarrelinearlyAsiantrade.Assuch,majorU.S.averagesslumpedmorethan1percenteachovernight,asinvestorseyedseveralspeeches
fromFedofficialsthathintedataninterest-ratehikenextmonth.ShanghaiCompositeindextradedat-0.89to3618.14,HangSengindextradedat1.11%to22604.04,
Japan'sbenchmarkNikkei225indextradedat0.06%to19703.78,SouthKorea'sKospiindextradeddownby-0.19%to1993.45levels.TheSGXNiftysuggestsagap
downopeningforourmarketsasitistradingat7774.50,downby37points.
WallStreetsuffereditsworstsessioninoveramonthonThursdayaslowercommoditypricesweighedonenergyandmaterialsstocksandcommentsbyaFederal
Reservepolicymakerhintedatanapproachinginterest-ratehike.Therouthitall10majorS&PsectorsandpushedtheDowandS&P500belowtheir200-daymoving
averages,whichsometradersbelieveportendsadditionaldeclines.InvestorsarekeepingawatchfuleyeonwhethertheFedinDecemberwillraiseratesforthefirst
timeinnearlyadecade,asiswidelyexpectedafterrecentstrongjobsdata.TheDowJonesindustrialaveragefell1.44percenttoendat17,448.07,theS&P500lost1.4
percentto2,045.97.TheNasdaqCompositedropped1.22percentto5,005.08.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
DCM Shriram Limited; Interim Dividend-Rs 1.20/- Per Share
Sundram Fasteners Limited; Interim Dividend - Re 0.85/- Per Share
Result Calendar:
BGRENERGY, CESC, COALINDIA, DHANBANK, EVEREADY, EVERONN, JINDALSAW, KSCL, MMTC,
NATCOPHARM, NECLIFE, ORISSAMINE, RESTIGE, SCI, SEAMECLTD, SOBHA, TIMETECHNO, TVTODAY,
VENUSREM, WOCKPHARMA, ZANDUREALT.
13th Nov 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr.No Deal Date Security Code Security Name Client Name Deal Type Quantity Price
1 10/11/2015 522209 YOGISUNG KAMLESHBHAI RAMESHBHAI LUNAGARIYA S 562505 10.11
2 10/11/2015 522209 YOGISUNG KAMLESHBHAI RAMESHBHAI LUNAGARIYA B 561405 10.03
3 10/11/2015 526957 UVBOARDS SAROJ MANILAL SHAH S 325000 15.19
4 10/11/2015 522209 YOGISUNG EUROPLUS ONE REALITY PRIVATE LIMITED S 279460 9.64
5 10/11/2015 526957 UVBOARDS CHETAN RASIKLAL SHAH B 200000 15.19
6 10/11/2015 522209 YOGISUNG B M TRADERS S 171124 9.90
7 10/11/2015 522209 YOGISUNG NIRAJ RAJNIKANT SHAH B 171124 9.91
8 10/11/2015 531867 UNITINT ARUNA DINESH SHAH S 166149 3.97
9 10/11/2015 531867 UNITINT ARUNA DINESH SHAH B 161064 3.90
10 10/11/2015 522209 YOGISUNG BP FINTRADE PRIVATE LIMITED B 140041 9.75

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
13th Nov 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website